Patients with an oral anticancer therapy (OAT), independent of the specific type of cancer
Conditions
Interventions
Group 1: Control group - First patients with OAT answer a digital questionnaire on medication literacy (AMIKO) and adherence (15-STARS). Afterwards they receive a digital basis education. After about
Sponsors
Pharmazeutisches Institut, Universität Bonn
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Malignant disease ((ICD-10 C00-97-, D45-48- or E24.1-diagnosis) - Independent intake of OAT for at least 3 months - Written consent to study participation - At least one improvable area of competence in part A of the AMIKO-questionnaire
Exclusion criteria
Exclusion criteria: - Insufficient knowledge of german - Cognitive impairments (e.g. dementia)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in medication literacy (AMIKO) between both data collections, comparison between control- and intervention group | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in adherence (15-STARS) between both data collections, general health literacy (HLS-EU-Q16), patient enablement (patient enablement instrument), quality of life (EQ-5D-5L) All secondary endpoints refer to the camparison between control- and intervention group. | — |
Countries
Germany
Contacts
Public ContactUlrich Jaehde
Pharmazeutisches Institut, Universität Bonn
Outcome results
None listed